Calendrier des promotions MiNK Therapeutics, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Paramètres de base
IPO date
2021-10-15
ISIN
US6036931029
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0.0222 | 10 |
| P/BV | -1.94 | 0 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -493.33 | 0 |
| ROE | 124.38 | 10 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 0 | 10 |
| Debt/Ratio | 0 | 10 |
| Debt/Equity | -1.25 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 391891.74 | 10 |
| Rentabilité Ebitda, % | 0.2398 | 1 |
| Rentabilité EPS, % | -35.29 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 7.29 $ | 0 $ | 0 $ | -5.49 % | 0 % | 0 % |
| common.calendar.number_days.7d | 7.7 $ | 0 $ | 0 $ | -10.52 % | 0 % | 0 % |
| common.calendar.number_days.30d | 7.5 $ | 6.89 $ | 7.7 $ | -8.13 % | 0 % | 0 % |
| common.calendar.number_days.90d | 9.32 $ | 6.89 $ | 9.23 $ | -26.03 % | 0 % | 0 % |
| common.calendar.number_days.180d | 0.7201 $ | 0.529 $ | 12.03 $ | 856.81 % | 0 % | 0 % |
| common.calendar.number_days.1y | 0.94 $ | 0.529 $ | 12.03 $ | 632.98 % | 0 % | 0 % |
| common.calendar.number_days.3y | 1.31 $ | 0.529 $ | 12.03 $ | 425.95 % | 0 % | 0 % |
| common.calendar.number_days.5y | 0 $ | 0.529 $ | 20.03 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 $ | 0.529 $ | 20.03 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 5.24 $ | 0.78 $ | 12.03 $ | 31.49 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. Garo H. Armen Ph.D. | Executive Chairman | N/A | 1953 (72 année) |
| Dr. Jennifer S. Buell Ph.D. | President, CEO & Director | 916.75k | 1975 (50 années) |
| Dr. Marcus Antonius van Dijk Ph.D. | Chief Scientific Officer | 458.28k | 1962 (63 année) |
| Ms. Christine M. Klaskin | Treasurer | 29.62k | 1966 (59 années) |
| Joy Zhou Ph.D. | Vice President & Head of CMC | N/A | |
| Mr. Robert Foster | Director Of Legal & Business Affairs |
Informations sur l'entreprise
Adresse: United States, New York. NY, 149 Fifth Avenue - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://minktherapeutics.com
Site web: https://minktherapeutics.com
